Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Influenza

In brief

This study will evaluate the safety and immunogenicity of the H3N2v MN 2010/AA ca live attenuated influenza vaccine (H3N2v LAIV) in healthy children and adults, 6 to 26 years old.

Key facts

Study ID

NCT02883426

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

1

Starts

2016-09-01

Last updated by the study team

2018-05-03

Who can join

Age: 6 and older, up to 26. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and non-pregnant females between 6 and 26 years of age inclusive.
• For children, presence of an adult caregiver who is in good health and able to understand and carry out the requirements
• General good health, without significant medical illness, physical examination findings, or significant laboratory abnormalities as determined by the investigator.
• Agree to storage of blood specimens for future research.
• Available for the duration of the trial.
• Willingness to participate in the study as evidenced by signing the informed consent document. Verbal assent will be obtained from minors 6 to 12 years of age and signed assent will be obtained from minors 13 and older.
• Female subjects of childbearing potential must agree to use effective birth control methods for the duration of the study (e.g., pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; intrauterine device; abstinence from heterosexual intercourse, surgical sterilization).

You may not qualify if…

• Anticipated direct routine [e.g. weekly or more frequent] contact with individuals younger than the designated age groups being studied as a result of household contact, occupation, or participation in day care with such individuals.
• Pregnancy as determined by a positive urine or serum human choriogonadotropin (β-HCG) test.
• Currently breast-feeding.
• Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history or physical examination.
• Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, affects the ability of the subject to understand and cooperate with the study protocol.
• Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.
• History of anaphylaxis.
• Allergy to oseltamivir as determined by subject report.
• Current diagnosis of asthma or reactive airway disease (within the past 2 years).
• Use of aspirin or salicylate-containing medications within 28 days prior to randomization or expected receipt through 28 days after final vaccination.
• History of Guillain-Barré Syndrome.
• Known history of HIV, hepatitis C, or active hepatitis B infection.
• Known immunodeficiency syndrome.
• Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs within 30 days prior to vaccination.
• Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to study vaccination.
• Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination.
• Travel to the Southern Hemisphere within 14 days prior to study vaccination.
• Travel on a cruise ship within 14 days prior to study vaccination.
• Receipt of another investigational vaccine or drug within 30 days prior to study vaccination.
• Allergy to eggs or egg products, gentamicin, or gelatin.
• Chronic use of intranasal medications.

Where it is running

• University of Rochester Medical Center (URMC), Vaccine Research Unit (Outpatient) — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.